Neuroendocrine Trans-Differentiation of Prostate Cancer

Neuroendocrine Trans-Differentiation of Prostate Cancer by Shusuka Akamatsu, Urk-Oncology Fellow, Department of Urologic Sciences, University of British Columbia

[@aleksandr4606]

Thank you for sharing this. But The outline seems confusing to me: Tumors with +ve NE markers should be treated as normal Adenocarcinoma. But we all know that this approach grants to the patient life expectancy of 4 - 12 months.
So what is the novelty here in this work then?